Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 44.52 USD -0.2%
Market Cap: 3.5B USD

Gross Margin
Veracyte Inc

68.5%
Current
68%
Average
63.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
68.5%
=
Gross Profit
339.3m
/
Revenue
495.1m

Gross Margin Across Competitors

No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

Veracyte Inc., founded in 2008, operates at the intriguing intersection of biotechnology and diagnostics, leveraging genomic insights to transform the landscape of disease diagnosis. The company's core mission is to improve the accuracy and efficiency of diagnostic testing, thus enabling better treatment decisions. Veracyte has woven innovation into its business model, creating a suite of genomic tests primarily for oncology and pulmonology. These tests are designed to resolve diagnostic ambiguity, particularly in cases where traditional tests might fall short. By harnessing advanced genomic technology, Veracyte empowers healthcare providers with definitive answers, thus facilitating timely and appropriate patient management. The company's revenue engine is driven by its extensive portfolio of products and services. At the heart of its operations is a series of diagnostic tests—such as Afirma for thyroid cancer, Percepta for lung cancer, and Envisia for idiopathic pulmonary fibrosis—each of which addresses key unmet medical needs. Veracyte generates income by selling these tests primarily to hospitals and healthcare providers, who in turn utilize the insights to bolster their clinical decision-making. Additionally, the company licenses its proprietary biobank and genomic platform to partners in research and pharma industries, unlocking further monetary streams. As payers increasingly recognize and reimburse the value of these precision diagnostic tools, Veracyte continues to strategically expand its market reach, reinforcing its role as a vital player in the biotech domain.

VCYT Intrinsic Value
HIDDEN
Show
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
68.5%
=
Gross Profit
339.3m
/
Revenue
495.1m
What is the Gross Margin of Veracyte Inc?

Based on Veracyte Inc's most recent financial statements, the company has Gross Margin of 68.5%.

Back to Top